Is the GAIN Act a turning point in new antibiotic discovery?

Canadian Journal of Microbiology

Volumn 59, Issue 3, 2013, Pages 153-156

  Brown, Eric D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antibacterial; Antibiotic; Antibiotic resistance; Drug discovery

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTICS; DRUG DEVELOPMENT; ECONOMIC ACTIVITY; INVESTMENT; LEGISLATION; MEDICINE; PRIVATE SECTOR; PUBLIC SECTOR;

ARTICLE; BACTERIAL GROWTH; COMBINATORIAL CHEMISTRY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESISTANCE; GENE EXPRESSION; GENOMICS; HIGH THROUGHPUT SCREENING; INVESTMENT; ORGANIZATION AND MANAGEMENT; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; HUMANS; LEGISLATION, DRUG; PRIVATE SECTOR; UNITED STATES;

UNITED STATES;

EID: 84875657153     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/cjm-2013-0089     Document Type: Article

References (35)

1. Boucher, H.W., and Corey, G.R. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5): S344-S349. doi:10.1086/ 533590.
2. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Jr., Gilbert, D., Rice, L.B., et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1): 1-12. doi:10.1086/595011. PMID:19035777.
3. Brown, E.D., and Wright, G.D. 2005. New targets and screening approaches in antimicrobial drug discovery. Chem. Rev. 105: 759-774. doi:10.1021/ cr030116o. PMID:15700964.
4. Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S., et al. 2010. The genetic landscape of a cell. Science, 327(5964): 425-431. doi:10.1126/ science.1180823. PMID:20093466.
5. D'Elia, M.A., Pereira, M.P., and Brown, E.D. 2009a. Are essential genes really essential? Trends Microbiol. 17: 433-438. doi:10.1016/j.tim.2009.08.005. PMID:19765999.
6. D'Elia, M.A., Millar, K.E., Bhavsar, A.P., Tomljenovic, A.M., Hutter, B., Schaab, C., et al. 2009b. Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis. Chem. Biol. 16: 548-556. doi:10.1016/j.chembiol.2009.04.009. PMID:19477419.
7. East, S.P., and Silver, L.L. 2013. Multitarget ligands in antibacterial research: progress and opportunities. Expert Opin. Drug Discov. 8: 143-156. doi:10.1517/ 17460441.2013.743991. PMID:23252414.
8. Ejim, L., Farha, M.A., Falconer, S.B., Wildenhain, J., Coombes, B.K., Tyers, M., et al. 2011. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7: 348-350. doi:10.1038/nchembio. 559. PMID:21516114.
9. European Centre for Disease Prevention and Control. 2009. ECDC/EMEA Joint technical report. The bacterial challenge: time to react. A call to narrow the gap between mutidrug-resistant bacteria in the EU and the development of new antibacterial agents. European Centre for Disease Prevention and Control, Stockholm, Sweden. Available from http://www.ecdc.europa. eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_ Time_to_React.pdf [accessed 4 February 2013].
10. Falconer, S.B., and Brown, E.D. 2009. New screens and targets in antibacterial drug discovery. Curr. Opin. Microbiol. 12: 497-504. doi:10.1016/j.mib.2009.07. 001. PMID:19651534.
11. Farha, M.A., Leung, A., Sewell, E.W., D'Elia, M.A., Allison, S.E., Ejim, L., et al. 2013. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to σ-lactams. ACS Chem. Biol. 8: 226-233. doi:10.1021/ cb300413m. PMID:23062620.
12. Hamad, B. 2010. The antibiotics market. Nat. Rev. Drug Discov. 9: 675-676. doi:10.1038/nrd3267. PMID:20811374.
13. Hillenmeyer, M.E., Fung, E., Wildenhain, J., Pierce, S.E., Hoon, S., Lee, W., et al. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science, 320(5874): 362-365. doi:10.1126/science.1150021. PMID: 18420932.
14. Ho, Y., Gruhler, A., Heilbut, A., Bader, G.D., Moore, L., Adams, S.-L., et al. 2002. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature, 415: 180-183. doi:10.1038/415180a. PMID: 11805837.
15. Infectious Disease Society of America. 2010. The 10 × '20 initiative': pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50(8): 1081-1083. doi:10.1086/652237. PMID:20214473.
16. Infectious Disease Society of America. 2012. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin. Infect. Dis. 55(8): 1031-1046. doi:10.1093/cid/cis688. PMID: 22891041.
17. Keating, T.A., Newman, J.V., Olivier, N.B., Otterson, L.G., Andrews, B., Boriack-Sjodin, P.A., et al. 2012. In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound. ACS Chem. Biol. 7(11): 1866-1872. doi:10.1021/cb300316n. PMID:22908966.
18. Kirby, T. 2012. Europe to boost development of new antimicrobial drugs. Lancet, 379: 2229-2230. doi:10.1016/S0140-6736(12)60964-7. PMID:22715506.
19. Klevens, R.M., Edwards, J.R., Tenover, F.C., McDonald, L.C., Horan, T., and Gaynes, R. 2006. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42: 389-391. doi:10.1086/499367. PMID:16392087.
20. Koul, A., Dendouga, N., Vergauwen, K., et al. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3: 323-324. doi:10. 1038/nchembio884. PMID:17496888.
21. Kumarasamy, K.K., Toleman, M.A., Walsh, T.R., et al. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10: 597-602. doi:10. 1016/S1473-3099(10)70143-2. PMID:20705517.
22. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23: 3-25. doi:10.1016/S0169-409X(96)00423-1. PMID:11259830.
23. Livermore, D.M. 2011. Discovery research: the scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 66: 1941-1944. doi:10.1093/jac/dkr262. PMID:21700626.
24. National Nosocomial Infections Surveillance. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control, 32(8): 470-485. doi:10.1016/j.ajic.2004.10.001. PMID:15573054.
25. Parsons, J.B., Frank, M.W., Subramanian, C., Saenkham, P., and Rock, C.O. 2011. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl. Acad. Sci. U.S.A. 108: 15378-15383. doi:10.1073/pnas.1109208108. PMID:21876172.
26. Payne, D.J., Gwynn, M.N., Holmes, D.J., and Pompliano, D.L. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6: 29-40. doi:10.1038/nrd2201. PMID:17159923.
27. Piddock, L.J.V. 2012. The crisis of no new antibiotics-What is the way forward? Lancet Infect. Dis. 12: 249-253. doi:10.1016/S1473-3099(11)70316-4. PMID: 22101066.
28. Projan, S.J. 2003. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6: 427-430. doi:10.1016/j.mib.2003.08.003. PMID: 14572532.
29. Silver, L.L. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24: 71-109. doi:10.1128/CMR.00030-10. PMID:21233508.
30. US Congress. 2011. Generating Antibiotic Incentives Now Act of 2011. 112th Cong., H.R. 2182/S. 1734.
31. Wimberly, B.T. 2009. The use of ribosomal crystal structures in antibiotic drug design. Curr. Opin. Investig. Drugs, 10: 750-765. PMID:19649920.
32. World Economic Forum. 2013. Insight Report. Global Risks 2013. 8th ed. World Economic Forum, Geneva, Switzerland. Available from http://www3. weforum.org/docs/WEF_GlobalRisks_Report_2013.pdf [accessed 4 February 2013].
33. Wright, G.D. 2011. Molecular mechanisms of antibiotic resistance. Chem. Commun. (Camb.), 47: 4055-4061. doi:10.1039/c0cc05111j. PMID:21286630.
34. Zalacain, M., Biswas, S., Ingraham, K.A., Ambrad, J., Bryant, A., Chalker, A.F., et al. 2003. A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J. Mol. Microbiol. Biotechnol. 6: 109-126. doi:10.1159/000076741. PMID:15044829.
35. Zhang, M.-Q., and Wilkinson, B. 2007. Drug discovery beyond the 'rule-of-five'. Curr. Opin. Biotechnol. 18: 478-488. doi:10.1016/j.copbio.2007.10.005. PMID: 18035532.